Presence of extended-spectrum beta-lactamase–producing Escherichia coli in fecal content of cattle from two slaughterhouses in Lima, Peru, 2023–2024

Descripción del Articulo

The indiscriminate use of antimicrobials has led enterobacteria such as Escherichia coli to develop a variety of resistance mechanisms such as the production of extended-spectrum beta-lactamases (ESBL). Beta-lactam antimicrobials including penicillins, monobactams, and cephalosporins are among the m...

Descripción completa

Detalles Bibliográficos
Autores: Villafana, Lorena, Ramos-Delgado , Daphne D., Arévalo-Rodríguez, Karla, Guevara Franco, Jose Alfredo, Carhuallanqui , Andrea
Formato: artículo
Fecha de Publicación:2024
Institución:Universidad Peruana Cayetano Heredia
Repositorio:Revistas - Universidad Peruana Cayetano Heredia
Lenguaje:español
OAI Identifier:oai:revistas.upch.edu.pe:article/6867
Enlace del recurso:https://revistas.upch.edu.pe/index.php/STV/article/view/6867
Nivel de acceso:acceso abierto
Descripción
Sumario:The indiscriminate use of antimicrobials has led enterobacteria such as Escherichia coli to develop a variety of resistance mechanisms such as the production of extended-spectrum beta-lactamases (ESBL). Beta-lactam antimicrobials including penicillins, monobactams, and cephalosporins are among the most widely used in both animals and humans; Therefore, the presence of ESBL-producing E. coli (ESBL-EC) has the ability to hydrolyze these antimicrobials, leading to resistance against this class of agents, which represents a potencial threat to human and animal health. This study aimed to determine the presence of ESBL-EC in fecal samples from cattle at two slaughterhouses in Lima, Peru. A total of 260 fecal samples from cattle were collected at two slaughterhouses: S1 (n=134) and S2 (n=126). Antibiotic discs of cefotaxime (CTX) 30 µg, aztreonam (ATM) 30 µg, ceftazidime (CAZ) 30 µg, cefpodoxime (CPD) 10 µg and ceftriaxone (CRO) were used as screening method. While, antimicrobials cefotaxime - clavulanic acid (CTX-CLA) (30/10 µg) and ceftazidime - clavulanic acid (CAZ-CLA) (30/10 µg) were used in combined disc method for ESBL-EC phenotypic confirmation. The interpretation results follow the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Finally, was determined that 23.5% (61/260) of fecal sample presented ESBL-EC. Our results demonstrate that cattle intended for human consumption are carriers of ESBL-EC representing a potential public health risk.   Keywords: ESBL-EC, antimicrobial resistance, cattle
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).